Wagner T, Fenneberg K
Eur J Clin Pharmacol. 1984;26(2):269-70. doi: 10.1007/BF00630298.
Cyclophosphamide (CP) is an alkylating cytostatic compound, which is activated to its cytotoxic form in the liver [1]. Since the therapeutic range of CP in the treatment of human tumours, is small like other cytostatics, a constant high bioavailability is essential for its oral administration. Although CP has become one of the most widely used cytostatics [2], there do not appear to have been any bioavailability investigations providing the necessary information. The development of a very sensitive gas chromatographic analytical method has now permitted investigation of the pharmacokinetics of oral CP in conventional clinical doses [3, 4, 5, 6].
环磷酰胺（CP）是一种烷化剂类细胞抑制剂，在肝脏中被激活为细胞毒性形式[1]。由于CP治疗人类肿瘤的治疗范围与其他细胞抑制剂一样窄，因此持续的高生物利用度对于其口服给药至关重要。尽管CP已成为使用最广泛的细胞抑制剂之一[2]，但似乎尚未有提供必要信息的生物利用度研究。一种非常灵敏的气相色谱分析方法的开发，现在使得对常规临床剂量口服CP的药代动力学进行研究成为可能[3,4,5,6]。
